A conditional error function approach for adaptive enrichment designs with continuous endpoints

Adaptive enrichment designs offer an efficient and flexible way to demonstrate the efficacy of a treatment in a clinically defined full population or in, eg, biomarker-defined subpopulations while controlling the family-wise Type I error rate in the strong sense. Frequently used testing strategies in designs with two or more stages include the combination test and the conditional error function approach. Here, we focus on the latter and present some extensions. In contrast to previous work, we allow for multiple subgroups rather than one subgroup only. For nested as well as nonoverlapping subgroups with normally distributed endpoints, we explore the effect of estimating the variances in the subpopulations. Instead of using a normal approximation, we derive new t-distribution-based methods for two different scenarios. First, in the case of equal variances across the subpopulations, we present exact results using a multivariate t-distribution. Second, in the case of potentially varying variances across subgroups, we provide some improved approximations compared to the normal approximation. The performance of the proposed conditional error function approaches is assessed and compared to the combination test in a simulation study. The proposed methods are motivated by an example in pulmonary arterial hypertension.

[1]  M. Humbert,et al.  Pulmonary arterial hypertension , 2013, Orphanet Journal of Rare Diseases.

[2]  Martin Posch,et al.  Design and estimation in clinical trials with subpopulation selection , 2018, Statistics in medicine.

[3]  C. Jennison,et al.  An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints † , 2011, Pharmaceutical statistics.

[4]  Martin Posch,et al.  Adaptive designs for subpopulation analysis optimizing utility functions , 2014, Biometrical journal. Biometrische Zeitschrift.

[5]  W. Lehmacher,et al.  Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.

[6]  Tim Friede,et al.  Aspects of Modernizing Drug Development Using Clinical Scenario Planning and Evaluation , 2010 .

[7]  K. Gabriel,et al.  SIMULTANEOUS TEST PROCEDURES-SOME THEORY OF MULTIPLE COMPARISONS' , 1969 .

[8]  L Di Scala,et al.  Time‐to‐event analysis with treatment arm selection at interim , 2011, Statistics in medicine.

[9]  P. Bauer,et al.  Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.

[10]  S. Pocock Group sequential methods in the design and analysis of clinical trials , 1977 .

[11]  M. Gladwin,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[12]  T. Friede,et al.  A conditional error function approach for subgroup selection in adaptive clinical trials , 2012, Statistics in medicine.

[13]  K. Gabriel,et al.  On closed testing procedures with special reference to ordered analysis of variance , 1976 .

[14]  H. Schäfer,et al.  A general statistical principle for changing a design any time during the course of a trial , 2004, Statistics in medicine.

[15]  Bart Spiessens,et al.  Adjusted significance levels for subgroup analyses in clinical trials. , 2010, Contemporary clinical trials.

[16]  H. Schäfer,et al.  Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches , 2001, Biometrics.

[17]  Nigel Stallard,et al.  Sequential designs for phase III clinical trials incorporating treatment selection , 2003, Statistics in medicine.

[18]  C. Mehta,et al.  Design and monitoring of multi‐arm multi‐stage clinical trials , 2017, Biometrics.

[19]  T. Friede,et al.  Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review , 2016, Journal of biopharmaceutical statistics.

[20]  Michael Rosenblum,et al.  Group sequential designs with prospectively planned rules for subpopulation enrichment , 2016, Statistics in medicine.

[21]  Sue-Jane Wang,et al.  Modification of Sample Size in Group Sequential Clinical Trials , 1999, Biometrics.

[22]  Tim Friede,et al.  Adaptive Designs for Confirmatory Clinical Trials with Subgroup Selection , 2014, Journal of biopharmaceutical statistics.

[23]  M. Landray,et al.  Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. , 2016, European heart journal.

[24]  S. Day Data monitoring committees in clinical trials: best practice, complexities and considerations , 2015 .

[25]  Gernot Wassmer,et al.  Designing Issues in Confirmatory Adaptive Population Enrichment Trials , 2015, Journal of Biopharmaceutical Statistics.

[26]  B. Turnbull,et al.  Group Sequential Methods , 1999 .

[27]  G. Wassmer,et al.  Robustness of testing procedures for confirmatory subpopulation analyses based on a continuous biomarker , 2018, Statistical methods in medical research.

[28]  Horst Olschewski,et al.  Updated clinical classification of pulmonary hypertension. , 2009, Journal of the American College of Cardiology.

[29]  Frank Bretz,et al.  Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: Applications and Practical Considerations , 2006, Biometrical journal. Biometrische Zeitschrift.

[30]  C. Dunnett A Multiple Comparison Procedure for Comparing Several Treatments with a Control , 1955 .

[31]  M Kieser,et al.  Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.

[32]  Tim Friede,et al.  A group‐sequential design for clinical trials with treatment selection , 2008, Statistics in medicine.

[33]  M. Kieser,et al.  Point estimation in adaptive enrichment designs , 2017, Statistics in medicine.

[34]  Frank Bretz,et al.  Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts , 2006, Biometrical journal. Biometrische Zeitschrift.

[35]  Michael Rosenblum,et al.  Multiple testing procedures for adaptive enrichment designs: combining group sequential and reallocation approaches. , 2016, Biostatistics.

[36]  Tim Friede,et al.  A Comparison of Methods for Adaptive Treatment Selection , 2008, Biometrical journal. Biometrische Zeitschrift.

[37]  M. Rahbar,et al.  Advancing clinical trial design in pulmonary hypertension , 2013, Pulmonary circulation.

[38]  Nigel Stallard,et al.  Estimation after subpopulation selection in adaptive seamless trials , 2015, Statistics in medicine.

[39]  P. Bauer,et al.  The reassessment of trial perspectives from interim data—a critical view , 2006, Statistics in medicine.

[40]  Tim Friede,et al.  Clinical trials with nested subgroups: Analysis, sample size determination and internal pilot studies , 2018, Statistical methods in medical research.

[41]  M. Posch,et al.  Optimizing Trial Designs for Targeted Therapies , 2016, PloS one.

[42]  T. Fleming,et al.  End points and clinical trial design in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.

[43]  Nigel Stallard,et al.  An Adaptive Group Sequential Design for Phase II/III Clinical Trials that Select a Single Treatment From Several , 2005, Journal of biopharmaceutical statistics.

[44]  Martin Posch,et al.  Optimized adaptive enrichment designs , 2017, Statistical methods in medical research.

[45]  Frank Bretz,et al.  Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology , 2009, Statistics in medicine.

[46]  Cyrus Mehta,et al.  Biomarker driven population enrichment for adaptive oncology trials with time to event endpoints , 2014, Statistics in medicine.

[47]  Frank Bretz,et al.  Adaptive Dunnett tests for treatment selection , 2008, Statistics in medicine.

[48]  J. Whitehead,et al.  A generalized Dunnett Test for Multi-arm Multi-stage Clinical Studies with Treatment Selection , 2012 .

[49]  M. Yeager,et al.  Proteomics of pulmonary hypertension: Could personalized profiles lead to personalized medicine? , 2015, Proteomics. Clinical applications.

[50]  W. Brannath,et al.  Recursive Combination Tests , 2002 .

[51]  J. Loyd Pulmonary arterial hypertension: insights from genetic studies. , 2011, Proceedings of the American Thoracic Society.